Serina Therapeutics, Inc. (SER) stock
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.36−0.05 (-3.87%)
Close on Nov 17, 2026Market cap $34.67MP/E –Yield –
Serina Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Serina Therapeutics's operating income for the twelve months ending Dec 31, 2025 was -$24.02M. For fiscal 2025 it was -$24.02M. The highest annual figure on record is -$3.13M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$24.02M | – |
| FY2024 | Dec 31, 2024 | -$17.05M | – |
| FY2023 | Dec 31, 2023 | -$3.13M | – |
| FY2022 | Dec 31, 2022 | -$6.98M | – |
| FY2021 | Dec 31, 2021 | -$7.93M | – |
| FY2020 | Dec 31, 2020 | -$10.10M | – |
| FY2019 | Dec 31, 2019 | -$12.56M | – |
| FY2018 | Dec 31, 2018 | -$11.25M | – |
| FY2017 | Dec 31, 2017 | -$6.66M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.21M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.39M | – |
| Q2 FY2025 | Jun 30, 2025 | -$5.57M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.86M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.55M | -2402.5% |
| Q3 FY2024 | Sep 30, 2024 | -$5.31M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.87M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.32M | – |
| Q4 FY2023 | Dec 31, 2023 | $241.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.46M | – |
| Q2 FY2023 | Jun 30, 2023 | -$945.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$962.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.05M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.87M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.67M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.21M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.19M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.33M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.40M | – |
| Q2 FY2020 | Jun 30, 2020 | -$2.37M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.01M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.72M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.28M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.44M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.12M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.36M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.20M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.13M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.55M | – |
See a number that looks wrong?